Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned a consensus recommendation of “Moderate Buy” from the seventeen research firms that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $59.13.

A number of analysts recently issued reports on the company. Chardan Capital lowered their price target on Intellia Therapeutics from $94.00 to $88.00 and set a “buy” rating for the company in a report on Thursday, October 24th. The Goldman Sachs Group cut their price target on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday. Evercore ISI raised shares of Intellia Therapeutics to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. dropped their price objective on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Finally, Citigroup lowered their target price on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a report on Friday.

Insiders Place Their Bets

In other news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at approximately $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its holdings in Intellia Therapeutics by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock worth $29,648,000 after buying an additional 98,865 shares during the period. Thrivent Financial for Lutherans acquired a new stake in shares of Intellia Therapeutics in the second quarter worth $679,000. American Century Companies Inc. raised its holdings in shares of Intellia Therapeutics by 23.8% during the second quarter. American Century Companies Inc. now owns 330,514 shares of the company’s stock worth $7,397,000 after purchasing an additional 63,550 shares during the last quarter. Vanguard Group Inc. lifted its position in Intellia Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock valued at $254,514,000 after purchasing an additional 155,579 shares during the period. Finally, Comerica Bank lifted its position in Intellia Therapeutics by 853.6% during the first quarter. Comerica Bank now owns 37,105 shares of the company’s stock valued at $1,021,000 after purchasing an additional 33,214 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Stock Up 2.4 %

Shares of Intellia Therapeutics stock opened at $16.34 on Tuesday. Intellia Therapeutics has a 52 week low of $15.35 and a 52 week high of $34.87. The company has a market capitalization of $1.66 billion, a PE ratio of -2.98 and a beta of 1.76. The stock’s fifty day moving average is $20.71 and its two-hundred day moving average is $22.72.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The company had revenue of $7.00 million for the quarter, compared to the consensus estimate of $19.68 million. Intellia Therapeutics’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.40) earnings per share. As a group, research analysts anticipate that Intellia Therapeutics will post -5.22 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.